A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: A prospective cohort study

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 741-750

  Li, Xiayu ^a   Tian, Jiong ^a   Wu, Jianyong ^a   He, Qiang ^a   Li, Heng ^a   Han, Fei ^a   Li, Qun ^a   Chen, Yilun ^a   Ni, Qin ^a   Chen, Jianghua ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

corticosteroid; hepatitis B virus infection; minimal change nephropathy; mycophenolate mofetil; slight mesangial proliferative glomerulonephritis

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VIRUS DNA;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS; HEPATITIS B VIRUS; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG INFECTION; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PROLIFERATIVE GLOMERULONEPHRITIS; PROSPECTIVE STUDY; PROTEINURIA; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; VIRUS REACTIVATION;

ADULT; CARRIER STATE; CHINA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; PREDNISONE; PROSPECTIVE STUDIES; REMISSION INDUCTION; YOUNG ADULT;

EID: 65549165362     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.011     Document Type: Article

References (22)

1. Zhiqiang G., Zhaohui D., Qinhuan W., et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 38 Suppl 3 (2004) S175-S178
2. Waldman M., Crew R.J., Valeri A., et al. Adult minimal-change disease: Clinical characteristics, treatment, and outcome. Clin J Am Soc Nephrol 2 (2007) 445-453
3. Miao L., Sun J., Yuan H., et al. Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation. Nephrology (Carlton) 11 (2006) 449-454
4. Lai K.N., Tam J.S., Lin H.J., and Lai F.M. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 54 (1990) 12-17
5. Yang C.H., Wu T.S., and Chiu C.T. Chronic hepatitis B reactivation: A word of caution regarding the use of systemic glucocorti-costeroid therapy. Br J Dermatol 157 (2007) 587-590
6. Lau S.C., Tse K.C., Lai W.M., and Chiu M.C. Use of prophylactic lamivudine and mycophenolate mofetil in renal transplant recipients with chronic hepatitis B infection. Pediatr Transplant 7 (2003) 376-380
7. Yi N.J., Suh K.S., Cho J.Y., et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 13 (2007) 451-458
8. Lubel J.S., Testro A.G., and Angus P.W. Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Intern Med J 37 (2007) 705-712
9. Zheng S., Chen Y., Liang T., et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 12 (2006) 253-258
10. Chan T.M., Fang G.X., Tang C.S., et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36 (2002) 1246-1252
11. Sumethkul V., Ingsathit A., Leelasa-Nguan P., and Jirasiritham S. Use of mycophenolate mofetil in kidney transplant recipients with viral hepatitis infection: Is it justified?. Transplant Proc 34 (2002) 3217-3219
12. Maes B.D., van Pelt J.F., Peeters J.C., et al. The effect of myco-phenolate mofetil on hepatitis B viral load in stable renal transplant recipients with chronic hepatitis B. Transplantation 72 (2001) 1165-1166
13. Gong Z.J., De Meyer S., Clarysse C., et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 6 (1999) 229-236
14. Wu J., Xie H.Y., Jiang G.P., et al. The effect of mycophenolate acid on hepatitis B virus replication in vitro. Hepatobiliary Pancreat Dis Int 2 (2003) 410-413
15. Bagga A., Hari P., Moudgil A., and Jordan S.C. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42 (2003) 1114-1120
16. Segarra A., Amoedo M.L., Martinez Garcia J.M., et al. Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis-a multicenter study. Nephrol Dial Transplant 22 (2007) 1351-1360
17. Afzal K., Bagga A., Menon S., et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 22 (2007) 2059-2065
18. Mendizábal S., Zamora I., Berbel O., et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 20 (2005) 914-919
19. Wheeler L.A., and Sheiner L.B. Clinical estimation of creatinine clearance. Am J Clin Pathol 72 (1979) 27-32
20. Huang J.J., Hsu S.C., Chen F.F., et al. Adult-onset minimal change disease among Taiwanese: Clinical features, therapeutic response, and prognosis. Am J Nephrol 21 (2001) 28-34
21. Nakayama M., Katafuchi R., Yanase T., et al. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 39 (2002) 503-512
22. Takei T., Koike M., Suzuki K., et al. The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. Clin Exp Nephrol 11 (2007) 214-217